At 12 months post-index date, the 1.5-mg dulaglutide dose remained the most common dosage formulation dispensed for both cohorts (65.6% cohort 1 and 71.2% cohort 2), while dulaglutide 0.75 mg was dispensed to 14.5% if cohort 1 and to 7.7% of cohort 2
Scientific studies have shown that tirzepatides dual GLP-1 and GIP action makes it more potent than semaglutides single GLP-1 action
Regular updates from the FDA and legal counsel are recommended to navigate this evolving landscape
Users describe being charged early, double-charged, or charged for medication they never received
At this point, switching to a dual or triple agonist like tirzepatide may provide additional benefit
In France, exact age was available, so patients aged 18 years were included